Biron F, Boibieux A, Tigaud S, Peyramond D
Service des Maladies Infectieuses, Hôpital de la Croix-Rousse, Lyon, France.
Pathol Biol (Paris). 1990 Nov;38(9):894-8.
Sixty patients with enterocolitis (36 men, 24 females), mean age thirty seven (12 to 84) have been treated with new quinolones. Two groups have been constituted. First group included patients without bacteremia despite enterocolitis. Among them, 9 patients suffered from shigellosis (8 S. flexneri, 1 S. sonnei). Twenty-two patients had a minor salmonellosis (13 S. typhimurium, 4 S. enteritidis, 1 S. blockley, 1 S. Virchow, 1 S. london, 1 S. baildon, 1 S. C2 group). Patients in the second group underwent a septicemic salmonellosis (18 S. typhi, 3 S. paratyphi, 8 other Salmonella serotypes). All patients but one received an oral treatment. Forty-seven patients received 400 mg/day ofloxacin, 8 patients 1.500 mg/day ciprofloxacin, 5 patients 800 mg/day pefloxacin. Treatment lasted an average of 10 days (5 to 31 days). Apyrexia was observed within an average of 3 days (1 to 8 days). Blood culture have always been sterile after a two days treatment duration. No more shigella or salmonella was found in feces, five days after beginning of treatment. No relapse has been observed within a 30 days mean background (1 to 180 days). Not any intolerance needed to stop treatment. Patients have been hospitalized on an average of 11 days. Therefore, new quinolones will represent an effective, well tolerated treatment for salmonellosis or shigellosis.
60例小肠结肠炎患者(36例男性,24例女性),平均年龄37岁(12至84岁)接受了新型喹诺酮类药物治疗。分为两组。第一组包括尽管患有小肠结肠炎但无菌血症的患者。其中,9例患有志贺菌病(8例福氏志贺菌,1例宋内志贺菌)。22例患有轻度沙门菌病(13例鼠伤寒沙门菌,4例肠炎沙门菌,1例布氏沙门菌,1例维尔肖沙门菌,1例伦敦沙门菌,1例拜尔顿沙门菌,1例C2群沙门菌)。第二组患者患有败血症性沙门菌病(18例伤寒沙门菌,3例副伤寒沙门菌,8例其他沙门菌血清型)。除1例患者外,所有患者均接受口服治疗。47例患者接受每日400mg氧氟沙星治疗,8例患者接受每日1500mg环丙沙星治疗,5例患者接受每日800mg培氟沙星治疗。治疗平均持续10天(5至31天)。平均3天(1至8天)内观察到退热。治疗持续2天后血培养始终无菌。治疗开始5天后粪便中未再发现志贺菌或沙门菌。在平均30天(1至180天)的随访期内未观察到复发。无需因任何不耐受而停止治疗。患者平均住院11天。因此,新型喹诺酮类药物将是治疗沙门菌病或志贺菌病的一种有效且耐受性良好的治疗方法。